1.Date of occurrence of the event:2022/10/13
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:OBI Pharma Inc. was informed by the patent office that patent for OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ has been granted by United States Patent and Trademark Office under the patent number 15/495,470.
OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system.
Clinical trial information:
https://www.clinicaltrials.gov/ct2/show/NCT03562637 (the United States)
https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B2%5D=2681 (Taiwan)
6.Countermeasures:None
7.Any other matters that need to be specified:New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.